Impact of Targeted Therapy on the Quality of End-of-Life Care for Patients with Non-Small-Cell Lung Cancer: A population-based study in Taiwan

Targeted therapies with epidermal growth factor receptor tyrosine kinase inhibitors have been widely used in the treatment of advanced non-small cell lung cancer (NSCLC). However, little research has focused on the use of targeted therapies at the end-of-life (EOL).

http://ift.tt/2yAP0Qo